.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Recent Updates on CDK4/6 Inhibitors for HR-Positive, HER2-Negative Metastatic Breast Cancer

Expert perspectives on recent evolutions with CDK4/6 inhibitors in the HR+, HER2- metastatic breast cancer treatment landscape.

EP. 1: Evolving Treatment Landscape of HR+/HER2- Metastatic Breast Cancer

June 15th 2022

Massimo Cristofanilli, MD, FACS, provides a historical overview of the HR+/HER2- metastatic breast cancer (mBC) treatment landscape.

EP. 2: HR+/HER2- Metastatic Breast Cancer: Treatment Armamentarium

June 15th 2022

Expert Harold Burstein, MD, PhD, breaks down the treatment armamentarium for patients with HR+/HER2- metastatic breast cancer.

EP. 3: Factors in Selecting Frontline Therapy for HR+/HER2- Metastatic Breast Cancer

June 22nd 2022

Shared insight on how best to select frontline therapy, alone or in combination, for patients with HR+/HER2- mBC.

EP. 4: PALOMA-2 and PALOMA-3: Time to Chemotherapy on Palbociclib + Endocrine Therapy

June 22nd 2022

Time-to-chemotherapy results of the PALOMA-2 and -3 trials in HR+/HER2- metastatic breast cancer, which combined frontline palbociclib and endocrine therapy.

EP. 5: MONALEESA-2 and MONALEESA-3: Frontline Ribociclib + Endocrine Therapy

June 29th 2022

Highlights from the MONALEESA-2 and -3 trials combining frontline ribociclib with endocrine therapy in patients with HR+/HER2- metastatic breast cancer.

EP. 6: MONARCH 2 and MONARCH 3: Pooled Analysis of Abemaciclib + Fulvestrant

June 29th 2022

Expert perspectives on the pooled analysis from MONARCH 2 and MONARCH 3, combining frontline abemaciclib with fulvestrant.